# Ivermectin, fenbendazole and mebendazole for cancer: what the evidence shows

People ask me about ivermectin and fenbendazole all the time. So I went through the human studies. These drugs are a legitimate research idea. They are not proven cancer treatments. Here's what the evidence actually shows.

![Article illustration](https://kevinwimer.com/media/5fd8625a-8609-471f-ac7a-6f6b3a65ab53)

Author: Kevin Wimer
Canonical URL: https://kevinwimer.com/cancer/resources/ivermectin-fenbendazole-cancer-evidence/
Stable ID: 96e907e1-d9f5-4fbf-b52e-dc7fd60bc54e
Revision: 33a85840-b373-4a51-865f-1667eda84f3c
Published: 2026-11-20T18:04:59.488Z
Updated: 2026-11-20T18:04:59.488Z
Reviewed: 2026-11-20

## Who this is for
For patients and caregivers who have heard ivermectin, fenbendazole or mebendazole can treat cancer and want to see what the human evidence shows before talking with their oncologist.

People bring up ivermectin and fenbendazole with me all the time. So I did what I do with every option for my own cancer: I went to the actual studies and data.

My cancer is driven by a single gene change called an ALK fusion. I'm on the third generation of a pill that targets it, and that pill is the reason I'm still here. So the question I ask about any option is simple: what does the human evidence show?

## The short version

Ivermectin is a legitimate research idea. It is not a proven cancer treatment.

Both of those are true at the same time.

## Why people believe it

The interest has real roots:

- Ivermectin is FDA approved for certain parasitic infections in people, and it's cheap and generic.
- Ivermectin and fenbendazole have shown anticancer effects in lab and animal studies.
- Generic drugs nobody can patent tend to get less research money.

That last one is real. But "nobody's paying to test it" is a very different claim from "it works and they're hiding it." There's evidence for the first. I haven't found any for the second.

Fenbendazole is different from ivermectin in one important way: it's a veterinary drug and isn't approved for use in people.

## What the human evidence shows

### The best ivermectin trial so far

A small phase 1/2 trial paired ivermectin with an immunotherapy drug in metastatic triple-negative breast cancer. The patients had already been through a median of 5 prior treatments. Of 8 patients who could be evaluated, 1 tumor shrank, 1 held stable and 6 progressed. The combination was well tolerated. There's no control group, and so far the results are a conference abstract from May 2025. You can't tell what ivermectin added.

### The biggest "real-world" study

This one followed 197 patients prescribed ivermectin plus mebendazole through a telemedicine service and reported glowing results. It was retracted in October 2026. Outcomes came from self-reported surveys, only 122 people completed follow-up, and many were also getting chemo, radiation, surgery or supplements at the same time. The journal said methodological problems undermined its central conclusions.

### The melanoma case people share

A 74-year-old man with metastatic melanoma declined standard treatment and took veterinary ivermectin paste, fenbendazole and several other over-the-counter products. His blood tumor marker dropped, then rose again, and a lymph node mass later grew. His doctors wrote that his own immune system clearing the cancer is at least as plausible an explanation as anything he took.

### The one human mebendazole trial

Mebendazole is a close cousin of fenbendazole. In a small trial in advanced gastrointestinal cancer, every patient who was treated stopped because their cancer progressed. The trial was planned for 30 patients and stopped early after 11 enrolled. The drug was well tolerated, but it had no anticancer effect.

So far, ivermectin's cancer benefit is unproven, and so is fenbendazole's.

## The dose problem

In the lab, these drugs work at concentrations far higher than people reach on approved doses. ASCO, the main US group of cancer doctors, says reaching those levels in humans would likely take doses far beyond established safety limits.

"Safe" also has a footnote. ASCO warns that high doses of ivermectin can cause loss of coordination, seizures, coma, dangerously low blood pressure and even death. Veterinary products aren't regulated for human use. Both drugs are processed by liver enzymes that can change how cancer drugs work. And fenbendazole has been linked to liver injury in published case reports.

## What about the success stories?

If someone took only ivermectin and beat cancer, that's amazing and I'd celebrate it.

But look closely at most stories. They're stacked: ivermectin plus fenbendazole plus supplements plus surgery or chemo. When five things happen at once, you can't credit one of them.

I can believe someone's improvement is real without knowing what caused it. That doesn't make the patient a liar. It makes the drug's contribution uncertain.

## What's actually being tested

- A University of Florida phase 2 trial will test ivermectin with immunotherapy in solid tumors. It's planned for 80 patients and wasn't yet recruiting as of its October 2026 update. That's how you find out.
- The breast cancer trial above is still listed as recruiting.

Meanwhile, in May 2026, ASCO recommended against using ivermectin or fenbendazole for cancer, or alongside cancer treatment, outside a clinical trial.

If you're curious, a trial is the safe way to try it. You can search [ClinicalTrials.gov](https://clinicaltrials.gov/) for ivermectin, and here's [how I look for trials](/cancer/resources/clinical-trials/).

## Why I'm not taking it

I'm not against ivermectin. I'm for evidence.

I have dozens of options with at least some human data behind them: next-generation targeted drugs, personalized vaccines, antibody-drug conjugates and cell therapies. I track them all.

If every one of those ran out and I had nothing left? Sure, I'd consider it as a Hail Mary. Anyone would.

Until then, the question isn't "is it being suppressed?" The question is "will a real trial show it works at a dose people can safely take?"

I hope the answer is yes. Let's run the trials and find out.

## Before you take anything

Talk to your oncologist first. Tell them about everything you take, including supplements and anything bought online or meant for animals. Questions worth asking:

1. Could this interact with my current treatment?
2. Is there a clinical trial testing it that I could join?
3. What would we watch for, and how would we know if it's causing harm?
4. What proven options do I still have?

I'm not a doctor and this isn't medical advice. It's what happened to me. Please talk to your care team before you change anything.

## Limits and context
A patient's summary of published evidence, not medical advice. Research changes, and new trial results could change this picture. Checked November 20, 2026. Never start, stop or add any drug or supplement without talking to your oncologist, because some can interact with cancer treatment.

## Relationships and disclosures
No paid placement. I have no investment, advisory role, paid partnership or other financial relationship with any drug maker or organization mentioned here.

## Sources
- [Ivermectin and cancer: what's real, what's hype](https://x.com/kevinace/status/2119817287679037868) — Kevin Wimer on X; experience; checked 2026-11-20; Personal experience, posted November 9, 2026. Kevin's review of the human evidence and why he isn't taking it. Not independent clinical evidence.
- [The one human trial of mebendazole](https://x.com/kevinace/status/2116995792598904882) — Kevin Wimer on X; experience; checked 2026-11-20; Personal experience, posted November 1, 2026. Kevin's summary of the mebendazole trial in advanced GI cancer. Not independent clinical evidence.
- [ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials](https://connection.asco.org/do/asco-clinical-notice-recommending-against-ivermectin-and-fenbendazole-cancer-treatment) — American Society of Clinical Oncology; official; checked 2026-11-20; Published May 26, 2026. Recommends against using ivermectin or fenbendazole to treat cancer, or alongside cancer treatment, outside a well-designed clinical trial; no robust clinical evidence of safety or effectiveness; preclinical effects would likely need doses far beyond established safety limits; high-dose ivermectin can cause ataxia, seizures, coma, low blood pressure and death; veterinary products lack FDA oversight for human use; both drugs are processed through liver enzymes that can affect cancer drugs. Fenbendazole is not approved for humans.
- [A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e13146) — Journal of Clinical Oncology (2025 ASCO Annual Meeting abstract); research; checked 2026-11-20; Published May 28, 2025. 9 patients accrued, heavily pretreated (median 5 prior lines); of 8 evaluable, 1 partial response, 1 stable disease, 6 progressed; the combination was safe and well tolerated. Conference abstract with no full text.
- [Ivermectin in combination with balstilimab or pembrolizumab in metastatic breast cancer (NCT05318469)](https://clinicaltrials.gov/study/NCT05318469) — ClinicalTrials.gov; research; checked 2026-11-20; Phase 1/2 study, recruiting, estimated enrollment 34; record last updated October 30, 2026. Single-group design with no control arm.
- [Ivermectin Combined With Immune-Checkpoint Inhibition in Cancer (ICONIC) (NCT07487805)](https://clinicaltrials.gov/study/NCT07487805) — ClinicalTrials.gov; research; checked 2026-11-20; University of Florida phase 2 study of intermediate- or high-dose ivermectin with immune checkpoint inhibitors in adult solid tumors; not yet recruiting; estimated enrollment 80; record last updated October 13, 2026.
- [Retraction: Real-world clinical outcomes of ivermectin and mebendazole in cancer patients](https://ar.iiarjournals.org/content/46/10/5877) — Anticancer Research; research; checked 2026-11-20; Retraction notice, October 2026 issue (PubMed lists the retraction date as October 1, 2026). The editor retracted the study because methodological and analytical problems undermine the reliability of its central clinical-benefit conclusions. No misconduct was alleged.
- [Real-world clinical outcomes of ivermectin and mebendazole in cancer patients (PubMed record, retracted)](https://pubmed.ncbi.nlm.nih.gov/42203321/) — PubMed, U.S. National Library of Medicine; research; checked 2026-11-20; 197 patients prescribed ivermectin and mebendazole through a telemedicine platform; outcomes from self-reported surveys; 122 completed 6-month follow-up; concurrent chemotherapy 27.9%, radiation 21.3%, surgery 19.7%, supplements 49.2%.
- [Case report: Metastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1907192/full) — Frontiers in Oncology; research; checked 2026-11-20; Published September 1, 2026. A 74-year-old man declined standard therapy and took veterinary ivermectin paste, fenbendazole and other over-the-counter products; ctDNA fell from 2.04 to 0.18 then rose to 0.93 MTM/mL and a nodal mass grew; the authors say spontaneous immune-mediated regression is at least as plausible; fenbendazole has been linked to drug-induced liver injury in case reports.
- [A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer](https://www.nature.com/articles/s41598-021-88433-y) — Scientific Reports; research; checked 2026-11-20; Published April 26, 2021. Planned for 30 evaluable patients; stopped early after 11 were enrolled. All 10 treated patients stopped because of progressive disease; only some reached the target blood level; the drug was well tolerated up to 4 g/day.

## Company facts
- **ASCO's position:** In a May 26, 2026 Clinical Notice, ASCO recommended against using ivermectin or fenbendazole to treat cancer, or alongside established cancer treatment, outside a well-designed clinical trial. Checked November 20, 2026. (Sources: asco-notice)
- **Largest real-world study:** A 197-patient survey study of ivermectin plus mebendazole in Anticancer Research was retracted in October 2026 over methodological problems with its clinical-benefit conclusions. Checked November 20, 2026. (Sources: anticancer-retraction, anticancer-original)

Topics: clinical-trials
Capabilities: 

Related record IDs: bcbf518f-872e-434c-b031-3d6c266ceaa4, 37f8559b-848c-41bc-9591-06013c785a00, 5209b08a-d248-40cd-bad2-dc8bf8518a23

Related X post: https://x.com/kevinace/status/2119817287679037868

Related X post: https://x.com/kevinace/status/2116995792598904882

Follow Kevin on X: https://x.com/kevinace

Educational information, not an individualized treatment recommendation.
